Search results
13 lut 2023 · In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting...
1 lut 2023 · Panels A-C show the number of clinical trials in breast cancer since early 2000, by immunotherapeutic approach (A), by trial setting (B), and by trial phase (C). Panel D shows the...
conventional breast cancer therapies in several aspects including patient selection, treatment-related adverse events (AEs) including immune-related AEs (irAEs), and response patterns. To support the oncology community and provide evidence-based and consensus-based recom-mendations on immunotherapy for breast cancer, the
The objective of this review is to describe the current status of immunotherapy in breast cancer, highlighting its potential in both early-stage and metastatic disease.
29 kwi 2024 · Abstract. Background: Significant progress has been made in immunotherapy of breast cancer (BC) with the approval of multiple immune checkpoint inhibitors (ICIs), particularly in early and metastatic triple-negative breast cancer (TNBC) settings.
1 sie 2021 · The evidence-based and consensus-based recommendations in this CPG are intended to give guidance to cancer care providers treating patients with breast cancer. Completed phase II/III...
This review article discusses current knowledge on immune checkpoint inhibitors in clinical practice, and provides an overview of a variety of markers evaluated to predict benefit of immunotherapy and of promising new strategies to enhance immune response and enable more patients to benefit from immunotherapy.
